Drug Combinations Compared for Kidney Cancer Recurrence Risk After Surgery

A large network meta-analysis has compared the immune checkpoint inhibitor-based drug regimens now used after nephrectomy in patients with renal cell carcinoma at high risk of recurrence, and the results reveal a clear trade-off between benefit and toxicity. Pooling six randomized controlled trials involving 5,838 patients, an international research team found that three strategies significantly delayed cancer recurrence compared with placebo or observation: pembrolizumab combined with belzutifan, durvalumab combined with tremelimumab, and pembrolizumab alone. The study, published in Cancer Immunology, Immunotherapy, also showed that the most effective combination came with a three- to five-fold increase in severe side effects, underscoring that patient selection will be critical as these therapies move into routine practice.

The analysis focused on disease-free survival, the length of time patients remain free of cancer after surgery, and overall survival. For disease-free survival, pembrolizumab plus belzutifan produced the strongest effect, with a hazard ratio of 0.51 (95 percent confidence interval 0.39 to 0.67), meaning a 49 percent reduction in the risk of recurrence or death relative to placebo or observation. This estimate rested on indirect evidence and carried moderate certainty.

Durvalumab plus tremelimumab followed with a hazard ratio of 0.65, and pembrolizumab monotherapy achieved a hazard ratio of 0.71 with high certainty. Notably, the combination of pembrolizumab and belzutifan was itself significantly better than pembrolizumab alone, with a hazard ratio of 0.72 and high certainty, a difference the authors judged both statistically and clinically meaningful. Overall survival told a similar but more limited story.

Pembrolizumab plus belzutifan showed a significant survival advantage over placebo or observation, with a hazard ratio of 0.51 (95 percent confidence interval 0.30 to 0.87), though this estimate relied on indirect evidence and carried moderate certainty. Pembrolizumab monotherapy also improved overall survival, with a hazard ratio of 0.66 and high certainty of evidence. Durvalumab plus tremelimumab did not show a significant overall survival benefit in the analysis.

The safety findings temper the enthusiasm generated by these efficacy results. Both doublet regimens, pembrolizumab plus belzutifan and durvalumab plus tremelimumab, were associated with a three- to five-fold increase in the risk of grade 3 or higher adverse events compared with placebo or observation. The authors concluded that the substantial toxicity of the combination regimens requires careful patient selection, balancing potential disease-free survival gains against distinct tolerability profiles.

Risk of bias was evaluated with the Cochrane RoB 2 tool, and certainty of evidence was graded using the CINeMA framework. The certainty ratings varied across findings: pembrolizumab monotherapy's benefits carried high certainty, while the pembrolizumab plus belzutifan estimates were rated moderate, partly because they depended on indirect evidence. Certainty was downgraded across several outcomes due to risk of bias stemming from open-label trial designs, indirectness, and imprecision, factors that readers should weigh when interpreting the magnitude of the reported effects.

The clinical context explains why these questions matter. Immune checkpoint inhibitor-based therapies have recently been introduced into the adjuvant management of renal cell carcinoma, the period after surgery when the goal is to reduce the risk of recurrence in patients whose tumors carry high-risk features following nephrectomy. The comparison between pembrolizumab alone and pembrolizumab plus belzutifan is a central finding of the analysis.

Adding belzutifan to pembrolizumab significantly improved disease-free survival relative to pembrolizumab monotherapy, with a hazard ratio of 0.72 and high certainty, and the doublet also showed a significant overall survival advantage over placebo or observation that the monotherapy shared. The trade-off is toxicity: the doublet's three- to five-fold increase in severe adverse events means that its larger recurrence-risk reduction comes with a heavier tolerability burden than either pembrolizumab alone or placebo. For clinicians and patients, the practical message is that no single adjuvant regimen dominates on all fronts.

The doublet regimens deliver larger reductions in recurrence risk but demand vigilance for severe adverse events, while pembrolizumab monotherapy carries high-certainty evidence for both disease-free and overall survival benefits. The authors emphasize that treatment decisions should balance potential disease-free survival benefits against each regimen's tolerability profile, with careful selection of patients most likely to benefit. As open-access research, the analysis provides a rigorous comparative foundation for a field where adjuvant therapy options for high-risk renal cell carcinoma have expanded rapidly.

Subject of Research: Comparative efficacy and safety of adjuvant immune checkpoint inhibitor-based therapies for high-risk renal cell carcinoma after nephrectomy

Article Title: Adjuvant immune checkpoint inhibitor-based systemic therapies for high-risk renal cell carcinoma after nephrectomy: systematic review and network meta-analysis

Article References: Miyajima, K., Tsuboi, K., Mori, K., Miszczyk, M., Lübbersmeyer, F., Goodarzi, K., Bret, D., Matsukawa, A., Urabe, F., Yanagisawa, T., Araki, M., Kimura, T., & Shariat, S. F. (2026). Adjuvant immune checkpoint inhibitor-based systemic therapies for high-risk renal cell carcinoma after nephrectomy: systematic review and network meta-analysis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04574-x

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04574-x

Keywords: renal cell carcinoma, immune checkpoint inhibitors, pembrolizumab, belzutifan, durvalumab, tremelimumab, network meta-analysis, disease-free survival, overall survival, adjuvant therapy, nephrectomy, adverse events